IQIRVO (elafibranor, Ipsen) is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
PBC is a rare, progressive, autoimmune cholestatic liver disease, in which the body attacks and gradually destroys the liver's small bile ducts, which if untreated can lead to cirrhosis and eventual liver failure.
The PBS listing of this first-in-class therapy increases therapeutic options for those with the condition.
PBC impacts an estimated 5,000 Australians, 95% of which are women, with symptoms such as fatigue and pruritus that can have a substantial impact on a person's quality of life.
According to hepatologist Dr Rohit Gupta, access to new options is very welcome.
"With up to 40% of Australian patients not responding adequately to first line treatment, access to new and innovative treatment options is incredibly important in addressing unmet patient needs," said Dr Gupta, who stressed the need for ongoing vigilance and monitoring.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Nov 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Nov 25
